FDA authorizes Amgen, Wyeth rheumatoid arthritis treatment

09/29/2004 | Forbes

The companies said their jointly developed Enbrel, administered in pre-filled syringes, is the first biologic to induce a major clinical response in victims of the disease, helping physicians measure improvement over a six-month period. The companies said they also got approval for new data on the treatment's effectiveness to be included in Enbrel labeling.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ